For the quarter ended June 2024, Edwards Lifesciences (EW) reported revenue of $1.39 billion, down 9.4% over the same period last year. EPS came in at $0.70, compared to $0.66 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $1.65 billion, representing a surprise of -16.19%. The company has not delivered EPS surprise, with the consensus EPS estimate being $0.70.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street ...